360數科 QFIN 深 滬
已收盤 01-09 16:00:00 美东时间
17.50
-0.640
-3.53%
華盛通- 最 高18.18
- 今 開18.17
- 成交量 213.62万股
- 最 低 17.20
- 昨 收 18.14
- 總市值 22.75亿
- 52周最高 47.50
- 市盈率 靜 3.05
- 換手率 1.64%
- 52周最低 17.20
- 委 比 -61.88%
- 總股本 1.30亿
- 歷史最高 47.50
- 量 比 1.49
- 振 幅 5.40%
- 歷史最低 2.08
- 每 手 1
- 風險率 8.52%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer
<p>RxSight, Inc. reported preliminary unaudited Q4 and full-year 2025 financial results, with Q4 revenue of approximately $32.6 million and full-year revenue of $134.5 million, exceeding November guidance. The company sold 28,611 LALs and 25 LDDs in Q4, and 109,615 LALs and 163 LDDs in 2025, reflecting a 10% and 12% procedure volume increase respectively. Cash, cash equivalents, and short-term investments totaled $228.1 million as of December 31,...
01-11 14:30
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics announced the approval of stock options for six non-executive employees under its 2018 Equity Inducement Plan. The options, totaling 42,000 shares, have an exercise price of $30.58, based on Spyre's closing price on January 2, 2026. The options vest over 10 years, with 25% exercisable after one year and the remainder vesting monthly. The grants comply with Nasdaq Listing Rule 5635(c)(4).
01-08 21:05
Abacus Global Management Chairman and CEO Jay Jackson Releases Shareholder Letter
Abacus Global Management reported record 2025 financial performance, including 124% YoY revenue growth and a strong transition to recurring revenue. The company raised its full-year adjusted net income guidance to $80–$84 million. Its integrated business model, spanning Life Solutions, Asset Group, ABL Tech, and Wealth Advisors, drives multiple revenue streams. Fee-related earnings are targeted to reach 70% of total revenue, up from 15%. Abacus c...
01-08 13:00
Anika Therapeutics Announces Leadership Transition
Anika Therapeutics announced that Stephen (Steve) Griffin, current CFO and COO, has been appointed President and CEO, effective February 1, 2026, succeeding Cheryl Blanchard, who will become Executive Chair of the Board. Griffin, with a track record of strategic transformation and operational excellence, will focus on accelerating growth, improving profitability, and delivering value to patients and shareholders.为确保总结不超过400字符，进一步精简： Anika Therap...
01-08 12:00
California Water Service Group Promotes Todd K. Peters and Thomas A. Scanlon
California Water Service Group promotes Todd K. Peters to Vice President, Engineering, and Thomas A. Scanlon to Vice President, Corporate Controller and Chief Accounting Officer, effective January 1, 2026. Peters joined the company in 1993 and previously served as Chief Engineering Officer, holding a Bachelor of Science in Civil Engineering and licenses in multiple states. Scanlon joined in 2010, most recently as Corporate Controller and Chief Ac...
01-07 22:00
Grayscale Investments® Announces Rebalancing of Multi-Asset Funds for Fourth Quarter 2025
Grayscale Investments has updated the weightings of its DeFi Fund, Smart Contract Fund, and AI Fund following their respective quarterly reviews in Q4 2025. The updated portfolios include specific allocations for each fund as of January 6, 2026. None of the funds generate income and all regularly distribute components to cover expenses, gradually reducing the value represented by their shares. Further details are available on grayscale.com.
01-07 21:15
ASP Isotopes Closes Acquisition of Renergen
<p>ASP Isotopes Inc. successfully acquired Renergen Limited, combining expertise in critical isotopes and helium production. The merged company aims to meet growing demand in high-tech industries, supported by $750 million in U.S. government funding to expand helium production. This strategic move positions the company to serve sectors like semiconductors, quantum computing, and clean energy, leveraging advanced technologies and Renergen's Virgin...
01-07 13:30
4DMT Provides Company Update and Anticipated Development Milestones for 2026
4D分子治疗公司宣布其4D-150湿性AMD III期临床试验入组人数超出预期，4FRONT-1试验预计将于2026年第一季度完成入组，截至2026年1月6日已有381名患者入组。PRISM IIb期数据和SPECTRA I/II期数据分别预计于2026年中和下半年公布。此外，公司任命Glenn Sblendorio为董事会成员，并计划于2026年1月14日在J.P. Morgan健康大会上展示战略展望。公司现金流充足，支持未来开发计划至2028年中。
01-07 13:00
Nova’s RPM North Drilling Confirms Further Resource Upside with East Extension Discovery
Nova Minerals reports strong gold results from its RPM North deposit, part of the Estelle Gold Project in Alaska. The 2025 drilling program confirmed broad, near-surface gold intersections and extended the eastern mineralized zone, with significant results including high-grade intervals. CEO Christopher Gerteisen highlights the potential for resource expansion and ongoing optimization studies. Further results and updates are expected in 2026.
01-07 11:30
Abacus Global Management Launches Asset-Based Finance Strategy
Abacus Global Management launches an asset-based finance (ABF) strategy led by Monty Cook and Elena Plesco, former executives from Varde Partners and KKR. The strategy combines institutional origination expertise with Abacus's proprietary insurance analytics to target the $20 trillion asset-based finance market. Focused on stable cash flows and low volatility, the ABF strategy will invest in asset-backed opportunities, including consumer credit, ...
01-06 21:05
